Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846485 | 0.93 | MEN1 (0.44) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL2722481 | 0.85 | HDAC3 (0.53) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6400630 | 0.85 | L3MBTL1 (0.47) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7983925 | 0.83 | L3MBTL1 (0.46) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL1844315 | 0.83 | L3MBTL1 (0.46) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7835952 | 0.83 | LTB4R (0.52) | L3MBTL1ALOX5 | |
| SCHEMBL9536343 | 0.82 | L3MBTL1 (0.45) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7983626 | 0.82 | L3MBTL1 (0.48) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7971622 | 0.82 | MC5R (0.46) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL25047455 | 0.81 | MEN1 (0.43) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20090239839-A1 | RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20070129348-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1623710-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239839-A1 | RECEPTOR ANTAGONIST | FSHR, NR0B2, NR4A3 | L3MBTL1 4377/4885HDAC3 427/4885HDAC1 841/4885 |
| US-20070129348-A1 | Receptor antagonist | FSHR, NR0B2, NR4A3 | L3MBTL1 4377/4885HDAC3 427/4885HDAC1 841/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | L3MBTL1 2375/4885HDAC3 451/4885HDAC1 295/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | L3MBTL1 2375/4885HDAC3 451/4885HDAC1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.